<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/GMXG-BH29" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method ITA-11: Measurement of Nanoparticle Effects on Cytotoxic Activity of NK Cells by Label-Free RT-CES System</p><p><b>Protocol Abbreviation:</b> ITA-11</p><p><b>Protocol Version:</b> 3<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/GMXG-BH29>http://dx.doi.org/10.17917/GMXG-BH29</a></p><p><b>Protocol File:</b> protocols/20240411_12-26-52-343_NCL_Method_ITA-11.pdf<p><b>File Title:</b> ITA-11</p><p><b>Description:</b></b> This document describes a protocol for assessing the effect of nanoparticles on the capacity of human natural killer (NK) cells to lyse tumorous target cells under in vitro conditions.  In this method, the NK92 cell line is used as the model for natural killer cells, and the hepatocellular carcinoma HepG2 cell line is used as the model for target cells.  Viability of HepG2 cells following the addition of untreated or nanoparticle-treated NK92 cells is monitored in real time using a real-time cell electronic system (RT-CES).<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>